Luz Angela Adriana Le Van

Dr. Luz Angela Adriana Le Van


Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2024 in Emerging Infectious Diseases
Verified
Journal Article
Open access
LVLuz Angela Adriana Le Van
Luz Angela Adriana Le Van
NRNazia Rahman
Nazia Rahman
RSReuel Sandy
Reuel Sandy
NDNelson Dozier
Nelson Dozier
HSHunter J. Smith
Hunter J. Smith
EGEric Garges
Eric Garges
Global Gonococcal Surveillance

20 June 2020 in bioRxiv
Verified
Preprint
Open access
PDF file
Aleksandra E. SikoraAleksandra E. Sikora
Aleksandra E. Sikora
CGCarolina Gomez
Carolina Gomez
LVLuz Angela Adriana Le Van
Luz Angela Adriana Le Van
BBBenjamin I. Baarda
Benjamin I. Baarda
SDStephen Darnell
Stephen Darnell
AJAnn Jerse
Ann Jerse
Bacterial surface lipoproteins are emerging as attractive vaccine candidates due to their biological importance and the feasibility of their large-scale production for vaccine manufacturing. The global prevalence of gonorrhea, resistance to antibiotics, and serious consequences to reproductive and neonatal health necessitate development of effective vaccines. Reverse vaccinology identified the surface-displayed L-methionine binding lipoprotein MetQ (NGO2139) and its homolog GNA1946 (NMB1946) as gonococcal and meningococcal vaccine candidates, respectively. Here, we assessed the suitability of MetQ for inclusion in a gonorrhea vaccine by examining MetQ conservation, its function in Neisseria gonorrhoeae ( Ng ) pathogenesis, and its ability to induce protective immune responses using a female murine model of lower genital tract infection. In-depth bioinformatics, phylogenetics and mapping the most prevalent Ng polymorphic amino acids to the GNA1946 crystal structure revealed remarkable MetQ conservation: ~97% Ng isolates worldwide possess a single MetQ variant. Mice immunized with rMetQ-CpG ( n =40), a vaccine containing a tag-free version of MetQ formulated with CpG, exhibited robust, antigen-specific antibody responses in serum and at the vaginal mucosae including secretory IgA. Consistent with the activity of CpG as a Th1-stimulating adjuvant, the serum IgG1/IgG2a ratio of 0.38 indicated a Th1 bias. Combined data from two independent challenge experiments demonstrated that rMetQ-CpG immunized mice cleared infection faster than control animals (vehicle, p <0.0001; CpG, p =0.002) and had lower Ng burden (vehicle, p =0.03; CpG, p <0.0001). We conclude rMetQ-CpG induces a protective immune response that accelerates bacterial clearance from the murine lower genital tract and represents an attractive component of a gonorrhea subunit vaccine.